Pharmacokinetics of Lamisil® in humans
- 1 January 1990
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 1 (sup2), 15-18
- https://doi.org/10.3109/09546639009089024
Abstract
The pharmacokinetics of terbinafine (Lamisil) have been studied in humans using both unlabelled and radiolabelled drug. Lamisil is well absorbed (> 70%) while maximal plasma concentrations of parent drug are reached within 2 hours following oral administration. Lamisil is extensively distributed to all tissues in the body with a total volume of distribution of approximately 1000 I (Vd). The half-life of elimination (β-phase) of Lamisil in man is approximately 16 hours. Lamisil is not excreted as an unchanged drug but is completely metabolized in the liver; 15 metabolites have been identified. Lamisil does not affect the metabolism of antipyrine, but its own metabolism is modified by the coadministration of either cimetidine or rifampicin.Keywords
This publication has 3 references indexed in Scilit:
- Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro.British Journal of Clinical Pharmacology, 1989
- Clinical pharmacokinetics of terbinafine (Lamisil)Clinical and Experimental Dermatology, 1989
- Antipyrine metabolism is not affected by terbinafine, a new antifungal agentEuropean Journal of Clinical Pharmacology, 1989